Compensation award — excluded from discretionary-purchase analysis.
Loading…
Reporting person on SEC Form 4
Christine A Poon
Director
Disclosures on record
28
Companies involved
2
Disclosure history
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Not classified as an open-market trade.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Director sold
~$1.79MReported value · 2,735 sh @ $653.50
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
Director sold
~$1.25MReported value · 1,915 sh @ $654.42
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
5,467 → 3,552 shares held−35% of their stake
A board member of Regeneron Pharmaceuticals sold $1.25M of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.
Director sold
~$467KReported value · 712 sh @ $656.50
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
3,452 → 2,740 shares held−21% of their stake
A board member of Regeneron Pharmaceuticals sold $467K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.
Director sold
~$424KReported value · 650 sh @ $652.68
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
8,852 → 8,202 shares held−7% of their stake
A board member of Regeneron Pharmaceuticals sold $424K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.
Director sold
~$255KReported value · 388 sh @ $657.29
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
2,740 → 2,352 shares held−14% of their stake
A board member of Regeneron Pharmaceuticals sold $255K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.
Director sold
~$66KReported value · 100 sh @ $655.10
Stock since the trade +12.5% · S&P 500 +11.1% · to Oct 1Traded 1 day after resultsStock up 12% in the previous month
3,552 → 3,452 shares held−3% of their stake
A board member of Regeneron Pharmaceuticals sold $66K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.